Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial

We present the interim results of the efficacy, immunogenicity, and safety of the two-dose schedules of TURKOVAC versus CoronaVac. This was a randomized, observer-blinded, non-inferiority trial (NCT04942405). Volunteers were 18–55 years old and randomized at a 1:1 ratio to receive either TURKOVAC or...

Descripción completa

Detalles Bibliográficos

Autores principales:	Mine Durusu Tanriover, Ozlem Altuntas Aydin, Rahmet Guner, Orhan Yildiz, Ilhami Celik, Hamdi Levent Doganay, Sukran Kose, Sila Akhan, Emin Halis Akalin, Zafer Sezer, Aykut Ozdarendeli, Serhat Unal, on behalf of the TURKOVAC Study Group
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2022-11-01
Colección:	Vaccines
Materias:	TURKOVAC CoronaVac efficacy safety COVID-19 vaccine
Acceso en línea:	https://www.mdpi.com/2076-393X/10/11/1865
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!